.Nature Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of patients along with HER2+ state-of-the-art breast cancer and also active or even stable brain metastases revealed regular intracranial activity and also systemic efficacy of T-DXd.